The clinical performance of the Idylla ctEGFR mutation assay was also evaluated by analyzing different NSCLC specimens previously genotyped by the standard testing methods in our lab (a custom capture-based NGS approach and the Cobas EGFR mutation assay v2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.